|
|
|
Journalists
Press releases
Press releases 2004
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Press releases are intended to journalists, analysts and investors.
Approval of the merger of Aventis with and into Sanofi-aventis
December 23, 2004
Sanofi-aventis to reorganise short-term financing
December 22, 2004
Sanofi-aventis receives Patent Office’s Notice of Allowance on its reissuance application for Lovenox ‘618 patent.
December 20, 2004
Taxotere® (docetaxel) regimen significantly improves survival in women with node positive early stage breast cancer
December 10, 2004
Update of patent litigation schedules in the United States for Plavix® and Lovenox®
December 9, 2004
First International Registry of Patients with Early Stage Breast Cancer Launched
December 7, 2004
Eloxatin™ (oxaliplatin for injection) based therapy combined with bevacizumab (Avastin™) significantly improves survival in patients with advanced colorectal cancer
November 29, 2004
Proposed Relocation of Aventis’ headquarters from Strasbourg to Paris
November 25, 2004
Aventis, part of the sanofi-aventis Group, announced termination of its agreements with Genta
November 9, 2004
Eloxatin™ (oxaliplatin for injection) receives FDA approval for the treatment of colon cancer following surgery (adjuvant treatment)
November 5, 2004
Possibility of increase in price of mandatory offer of sanofi-aventis to shareholders of Hoechst AG to EUR 56.50 per Hoechst share
November 4, 2004
European Union Approval for Taxotere® (docetaxel) in Prostate Cancer
November 4, 2004
Aventis Receives Approvable Letter from U.S. Food and Drug Administration for Alvesco® (ciclesonide) for Treatment of Persistent Asthma
October 26, 2004
Sales momentum maintained, rapid progress on integration - Sustained growth in proforma combined net sales: 10.5% for the first nine months of 2004
October 21, 2004
Proposed Merger of Aventis into sanofi-aventis
October 14, 2004
Strengthening of the Alliance on Actonel® between the Sanofi-aventis Group and Procter & Gamble
October 8, 2004
sanofi-aventis launches its mandatory offer to the shareholders of Hoechst Aktiengesellschaft. Offer document cleared by German Financial Supervisory Authority (BaFin)
October 1, 2004
New appointments in the sanofi-aventis Group
September 22, 2004
Appointments at the Communications Department of the sanofi-aventis Group
September 22, 2004
Eloxatin® to receive expanded indication in Europe for early stage colorectal cancer treatment
September 17, 2004
The sanofi-aventis Group thanks its team members and shareholders and launches its new visual identity
September 16, 2004
Final results of sanofi-aventis’ offer for Aventis: After subsequent offering period, sanofi-aventis holds 98.03% of Aventis share capital
September 16, 2004
sanofi-aventis’ offer for Aventis subsequent offering period has expired
September 7, 2004
Appointments of a hundred managers in 70 countries in the sanofi-aventis group
September 6, 2004
Agnès Garcia-Gibot is appointed Director of International Internal Communications and Corporate Image for Sanofi-Aventis
September 1, 2004
Excellent first half of 2004 for Sanofi-Synthelabo. Strong growth in EPS* in the first half of 2004: 21.6% on a reported basis; 32.8% at 2003 exchange rates
August 31, 2004
Olivier Jacquesson becomes head of Business Development
August 30, 2004
Mandatory Publication pursuant to Sections 35 sub-sec. 1, 10 sub-sec. 3 Securities Acquisition and Takeover Act (WpÜG) – Mandatory Offer
August 23, 2004
Birth of Sanofi-Aventis, the world's 3rd largest pharmaceutical company, ranking number 1 in Europe
August 20, 2004
Broad success of Sanofi-Synthélabo’s offer for Aventis
August 12, 2004
Sanofi-Synthélabo’s offer for Aventis. Provisional results of the offers
August 9, 2004
Sanofi-Synthélabo’s offer for Aventis. Tender period has expired
July 31, 2004
FTC Clears Sanofi-Synthélabo’s offer for Aventis shares
July 29, 2004
Very strong sales growth in the first half of 2004: consolidated sales: 4,460 million euros, up 18.9% on a comparable basis, up 14.3% on a reported basis, developed sales: up 25.5% on a comparable basis
July 21, 2004
Teva Pharmaceuticals’ ANDA does not challenge the product patent for Avapro® (irbesartan)
July 20, 2004
The U.S. Federal Trade Commission’s Bureau of Competition and Economics has completed its review of Sanofi-Synthélabo's proposed acquisition of Aventis
July 15, 2004
Sanofi-Synthelabo and Pfizer conclude an agreement on the divestment of Campto® (irinotecan) conditional upon completion of Sanofi-Synthelabo's offer for Aventis
June 25, 2004
Annual general meeting
June 24, 2004
Sanofi-Synthelabo’s offer for Aventis : expiration date of offers
June 23, 2004
Closing date of Sanofi-Synthelabo's offer on Aventis postponed to July 30, 2004
June 22, 2004
Draft structure of Sanofi-Aventis Management Committee
June 21, 2004
Sanofi-Synthelabo's offer for Aventis : Adjustment of offer terms on approval of Aventis dividend
June 14, 2004
New indications for Arixtra® in the United States: the treatment of acute deep venous thrombosis and acute pulmonary embolism
June 4, 2004
ELOXATIN™ study in New England Journal Of Medicine demonstrates significant benefit over standard therapy in early stage colon cancer
June 3, 2004
Sanofi-Synthelabo's offer for Aventis. Expiration date of offers
June 1, 2004
Sanofi-Synthelabo's offer for Aventis : U.S. offer extended to Wednesday, June 30, 2004
May 26, 2004
General Meeting of Sanofi-Synthelabo Shareholders: Sanofi-Synthelabo’s Offer for Aventis
May 26, 2004
Sanofi-Synthelabo’s Shareholders Meeting and offer for Aventis
May 14, 2004
Sanofi-Synthélabo’s Offer for Aventis: request for Additional Information from the Federal Trade Commission
May 5, 2004
Postponement of Sanofi-Synthélabo General Meeting of May 24, 2004
May 4, 2004
Approval by the European Commission of the planned acquisition of Aventis by Sanofi-Synthelabo
April 27, 2004
Agreement between Sanofi-Synthelabo and Aventis to create Sanofi-Aventis
April 26, 2004
1st quarter 2004 sales :Sustained and very strong sales growth
April 22, 2004
Press release dated April 15, 2004
April 15, 2004
Sanofi-Synthelabo to sell to GlaxoSmithKline Arixtra®, Fraxiparine® and Notre Dame de Bondeville plant
April 13, 2004
Sanofi-Synthélabo Commences U.S. Offer for Aventis
April 13, 2004
Sanofi-Synthélabo's Offer for Aventis
April 5, 2004
Alfuzosin 10 mg OD (Xatral® OD) shows beneficial effect in patients with acute urinary retention
March 25, 2004
Financing of the offer on AVENTIS
March 19, 2004
Publication of financial statements 2003
March 12, 2004
Two pivotal studies indicate ACOMPLIA™ (rimonabant) offers a novel approach to cardiovascular risk management in overweight/obese people and smokers
March 9, 2004
Outstanding 2003 performance : sales growth, 15.6% on a comparable basis, 2003 EPS growth, 21.5%, very positive R&D results
February 16, 2004
Sanofi-Synthelabo to acquire all of Taisho's 49% interest in the joint venture company Sanofi-Synthelabo-Taisho Pharmaceutical Co.
February 4, 2004
Sanofi-Synthelabo announces offer for Aventis's shares
January 26, 2004
Continued strong consolidated sales growth in 2003: 15.6 % on a comparable basis 8.1% on a reported basis
January 22, 2004
ELOXATIN™ submitted in the United States and in Europe for the adjuvant treatment of patients with colon cancer
January 19, 2004
Press release dated January 16, 2004
January 16, 2004
Eloxatin™ (oxaliplatin for injection) approved in the United States for the 1st line treatment of metastatic colorectal cancer
January 12, 2004
Sanofi-Synthelabo to acquire all interests in Arixtra®, idraparinux and other oligosaccharides from Organon
January 7, 2004
ELOXATIN® is becoming a cornerstone therapy for the treatment of metastatic colorectal cancer in Europe
January 7, 2004
|
|
